randomly assigned

Related by string. randomly assign * Randomly : randomly selected . randomly paired . randomly assigning . randomly sampled . randomly selected households / assigning . assigns . Assigned . Assign : Fitch Ratings assigns . Assigned Names . Internet Assigned Numbers . Moody assigns * Researchers randomly assigned . THIS STUDY randomly assigned . randomly assigned cornea *

Related by context. All words. (Click for frequent words.) 78 randomized 66 randomized #:# 62 n = 61 Researchers randomly assigned 57 randomly assigning 57 placebo 56 randomized #:#:# 56 inactive placebo 55 randomized controlled trial 55 mg d 54 randomized placebo controlled 54 randomly assign 54 blind placebo 53 prospectively randomized 53 randomized double 53 blinded placebo controlled 53 blind randomized 53 prospective cohort 53 #mg QD [002] 53 weekly subcutaneous injections 53 randomized clinical 52 normotensive 52 placebo capsules 52 saline placebo 51 trials RCTs 51 double blind placebo 51 randomized controlled 51 randomize 51 dose dose escalation 51 placebo controlled 51 mcg kg 51 nonobese 51 multicenter randomized 51 double blinded randomized 50 prospective observational 50 nulliparous women 50 darunavir ritonavir 50 mg Pycnogenol 50 randomisation 50 DCCT 50 prostates removed 50 tenofovir emtricitabine 50 daily subcutaneous injections 50 nonrandomized 50 antiretroviral naïve 49 irbesartan 49 antiretroviral naive 49 randomly selected 49 blind randomized placebo 49 prospective randomized 49 controlled multicenter 49 mcg albinterferon alfa 2b 49 randomized crossover 49 dietary questionnaires 49 methotrexate monotherapy 49 FOLFOX 49 underwent percutaneous coronary 49 symptomatic BPH 49 mg QD 49 insulin detemir 49 diuretic chlorthalidone 49 multicenter 48 dummy pill 48 TDF FTC 48 evaluable 48 #mg/m# [002] 48 q#h 48 oral prednisone 48 undergone radical prostatectomy 48 #mg/day [001] 48 pegylated interferon alfa 2b 48 multicenter study 48 atazanavir ritonavir 48 dose regimens 48 HF ACTION 48 ascending doses 48 multicenter randomized controlled 48 #:# randomization 48 intravenous dose 48 abacavir lamivudine 48 underwent CABG 48 3TC lamivudine Epivir 48 active comparator 48 multicentre randomized double 48 double blinded placebo 47 histologically confirmed 47 blind placebo controlled 47 randomized blinded 47 #mg dosing 47 OADs 47 dummy pills 47 Raloxifene Evaluation MORE 47 premenopausal 47 conjugated equine estrogen 47 retrospective cohort study 47 cluster randomized controlled 47 treatment naïve genotype 47 virologic failure 47 male Wistar rats 47 ug dose 47 randomized multicenter 47 neoadjuvant 47 randomly chosen 47 randomized controlled trials 47 undergoing coronary angiography 47 randomization 47 mcg 47 histologically proven 47 mg RDEA# 47 nondepressed 47 comparator arm 47 dosing cohort 47 LEXIVA r 47 de novo kidney transplant 47 8mg/kg 47 blind randomized controlled 46 ascending dose 46 REYATAZ r arm 46 overnight polysomnography 46 multicentre 46 safety tolerability pharmacokinetics 46 dummy capsules 46 HIV uninfected 46 retrospective cohort 46 intravenous bolus 46 Baseline characteristics 46 treatment naive genotype 46 preoperative chemotherapy 46 controlled dose escalation 46 observational study 46 multicenter randomized double 46 venlafaxine XR 46 risperidone Risperdal 46 mg ustekinumab 46 #mg QD [001] 46 postintervention 46 mg dose 46 Primary endpoints 46 dose titration 46 mg Lucentis 46 continuous intravenous infusion 46 undergone hysterectomies 46 genotyped 46 nondiabetic 46 NSTE ACS 46 blinded randomized 46 Myocardial Infarction Study 46 mcg BID 46 mg BID 46 mg/m2 dose 46 blinded randomized placebo controlled 46 efavirenz EFV 46 mg administered orally 46 weekly intravenous infusions 46 mcg linaclotide 46 mg simvastatin 45 dalteparin 45 PREZISTA r 45 retrospectively analyzed 45 peginterferon alfa 2b 45 docetaxel prednisone 45 #mg/kg [002] 45 administered subcutaneously 45 nortriptyline 45 4mg/kg 45 GATTEX therapy 45 montelukast 45 ragweed allergic 45 euthyroid 45 intramuscular injections 45 prospectively evaluated 45 prospectively stratified 45 blinded placebo 45 FDG PET scans 45 citalopram 45 5-FU/LV 45 EURIDIS 45 sham acupuncture 45 PREZISTA ritonavir 45 HBeAg positive 45 saline injections 45 prospective randomized multicenter 45 placebo intravenously 45 multicenter prospective 45 Atherosclerosis Risk 45 dosing cohorts 45 sertraline 45 antihypertensive therapy 45 placebo controlled dose escalation 45 cohort 45 nadroparin 45 retrospectively reviewed 45 Clinical Antipsychotic Trials 45 mg 45 milligram doses 45 underwent radical prostatectomy 45 stage IIIb IV 45 bupropion SR 45 UKPDS 45 #mg/m# [001] 45 mg/m2 45 APTIVUS r 45 dose escalation study 45 collected saliva samples 45 Randomized controlled 45 CARDIA 45 LPV r 45 dose escalation phase 45 peginterferon 45 placebo dexamethasone 45 intra articular injection 44 hsCRP levels 44 placebo controlled randomized 44 multicentre randomized 44 placebo controlled Phase 44 unfractionated heparin 44 undergone splenectomy 44 blinded randomized controlled 44 DMARD therapy 44 adjuvant tamoxifen 44 postmenopausal women 44 plus ribavirin 44 GnRH agonist 44 mg subcutaneously 44 Acute Coronary Syndromes ACS 44 dosage regimens 44 RLAI 44 prospective multicenter 44 desvenlafaxine succinate 44 tenecteplase 44 subcutaneous doses 44 intradermal injections 44 carboplatin 44 subcutaneous dose 44 NOXAFIL Oral Suspension 44 PARTNER Trial 44 glioma tumors 44 ritonavir boosted atazanavir 44 flutamide 44 Folfox 44 mcg doses 44 stage IIIB 44 placebo PBO 44 μg 44 #mg ATC 44 subcutaneous injections 44 mg TID 44 mg qd 44 retrospective observational study 44 Intervention Trial 44 interferon alfa 2a 44 REVIVE Diabetes 44 RRMS patients 44 Randomized 44 underwent liver transplantation 44 Q2W 44 randomized multicentre 44 inert placebo 44 interferon alfa 2b 44 primary hypercholesterolemia 44 lamivudine monotherapy 44 AMOR IPAT 44 glucose intolerant 44 plus methotrexate 44 multicentre study 44 HIV seronegative 44 enrolled 44 WHIMS 44 nondiabetic patients 44 monotherapy 44 lopinavir r arm 44 placebo controlled Phase III 44 medroxyprogesterone acetate 44 multicenter randomized placebo controlled 44 ritonavir boosted 44 mg FV 44 bivariate analyzes 44 patients undergoing percutaneous 44 unblinded 44 p = 44 HbA1c levels 44 relapsed MM 44 aspirin clopidogrel 44 oral rivaroxaban 44 DAS# scores 44 placebos 44 lopinavir ritonavir 44 unstable angina UA 44 AIR CF1 44 prospectively defined 44 adjunctive placebo 44 prospective multicenter randomized 44 TMC# C# 44 achieved ACR# 43 lopinavir r 43 adalimumab 43 Communities ARIC study 43 preintervention 43 #mg/day [002] 43 venlafaxine ER 43 intermittent dosing 43 limiting generalizability 43 eribulin 43 FOLFOX4 alone 43 mg dosed once 43 conducted retrospective cohort 43 mg kg dose 43 pegylated alpha interferon 43 randomized placebo 43 evaluable patients 43 zidovudine lamivudine 43 HCV SPRINT 43 Polyp Prevention Trial 43 d4T 43 bolus injection 43 peg IFN 43 Phase III randomized 43 peginterferon alfa 2a 43 longitudinal cohort study 43 oral prednisolone 43 multicentre prospective 43 metformin sulfonylurea 43 lispro 43 Prostate Lung Colorectal 43 Pred Forte 43 events AEs 43 underwent surgical resection 43 postmenopausal osteoporotic women 43 HCV RESPOND 2 43 concomitant medications 43 ng dl 43 label multicenter 43 oxycodone CR 43 doxazosin 43 Framingham Offspring 43 chlorambucil 43 receiving highly emetogenic 43 paclitaxel eluting stents 43 timepoints 43 dapagliflozin plus 43 recurrent glioblastoma multiforme 43 receiving ISENTRESS 43 valproate 43 placebo controlled clinical trials 43 echinacea tablets 43 mg kg 43 chewed sugarless gum 43 substudy 43 prospective randomized placebo 43 relapsing remitting MS 43 nonmetastatic 43 cognitively normal 43 prior chemotherapy regimens 43 serum estradiol 43 azathioprine 43 SORT OUT III 43 sirolimus eluting stent 43 Wistar rats 43 % CI #.#-#.# [003] 43 pegylated interferon alfa 2a 43 pegylated interferon 43 partial remissions 43 label dose escalation 43 achieved sustained virologic 43 prospective randomized controlled 43 CHOP chemotherapy 43 thalidomide dexamethasone 43 mucositis stomatitis 43 dirucotide MBP# 43 verum acupuncture 43 Sprague Dawley rats 43 randomized multicenter trial 43 mild renal insufficiency 43 randomized clinical trials 43 transfemoral 43 naïve HCV 43 buprenorphine implants 43 abdominal subcutaneous fat 43 Peg IFN 43 non splenectomized 43 titrated 43 ritonavir boosted lopinavir 43 sedentary postmenopausal 43 placebo controlled clinical 43 blind multicenter 43 stavudine d4T 43 genotypic resistance 43 antihypertensive medications 43 mg/m2 IV 43 nevirapine Viramune 43 randomized blinded placebo 43 Study ARIC 43 intramuscularly 42 #mg q8h 42 valacyclovir 42 copies mL 42 certolizumab 42 PEG Intron ® 42 multicenter Phase II 42 adefovir 42 -#.# log# copies mL 42 adjunctive ABILIFY 42 TEAEs 42 unmedicated 42 ABC/3TC 42 hypercholesterolemic 42 melphalan prednisone 42 Cohort 42 milliliters mL 42 oral levofloxacin 42 evaluable subjects 42 dose cohorts 42 CC genotype 42 label dose titration 42 nab paclitaxel 42 fallopian tube carcinoma 42 tirofiban 42 Communities ARIC Study 42 multicenter multinational 42 statistically significant differences 42 q8h 42 hypogonadal men 42 pramlintide 42 intravenous doses 42 CATIE AD 42 Carotid Revascularization Endarterectomy vs. 42 landmark ATHENA 42 hyperlipidemic 42 ddI 42 docetaxel 42 triamcinolone 42 patientswith 42 prospectively enrolled 42 highest tertile 42 placebo dummy pill 42 Kaplan Meier estimate 42 adenotonsillectomy 42 NHANES III 42 DAPT 42 observational cohort 42 virological failure 42 divalproex sodium 42 drank caffeinated 42 aromatase inhibitor therapy 42 pregabalin 42 coronary angiograms 42 amoxicillin clavulanate 42 fasting triglyceride levels 42 oral sapacitabine 42 folic acid vitamin B6 42 COU AA 42 ziprasidone 42 nonpsychotic 42 moderate renal impairment 42 dose cohort 42 comparing XIENCE V 42 lamotrigine 42 BoNTA 42 systolic blood pressure 42 Multicenter AIDS 42 daily Infergen 42 Swedish Mammography Cohort 42 Multicenter 42 ribavirin RBV 42 drank pomegranate juice 42 safety tolerability 42 HBeAg negative patients 42 metastatic HRPC 42 Exclusion criteria 42 prospective nonrandomized 42 ascending dose study 42 mitoxantrone 42 lamivudine 42 dose escalation clinical 42 TAXOTERE R 42 knobby polyps 42 intravenous dosing 42 P = .# 42 quartiles 42 divalproex 42 microgram kg 42 prespecified 42 CrCl 42 ribavirin therapy 42 single ascending dose 42 gemcitabine 42 infliximab monotherapy 42 Radiation Therapy Oncology 42 bolus dose 42 sham injections 42 oral antidiabetes 42 cilostazol 42 eptifibatide 42 XELOX 42 titrated glipizide 42 % CI #.#-#.# [002] 42 primary percutaneous coronary 42 protease inhibitor PI 42 Flu Cy 42 mcg QD 42 visilizumab 42 Pegasys plus Copegus 42 acarbose 42 nonsignificant difference 42 intima media thickness 42 hematopoietic cancers 42 relapsers 42 buprenorphine naloxone 42 PREZISTA rtv 42 Wisconsin Sleep Cohort 42 tibolone 42 recurrent malignant glioma 42 prednisone prednisolone plus 42 neuropsychological tests 42 zonisamide SR 42 ACTIVE W 42 stratified 42 male Sprague Dawley 42 everolimus eluting stents 42 patients undergoing CABG 42 ethambutol 42 chemoradiation therapy 42 inhaled tobramycin 42 diagnosed GBM 42 SSRI citalopram 42 designated HVTN 42 plus prednisone 42 tamoxifen therapy 42 nonadherent 42 cystectomy 42 #mg BID [001] 42 avosentan 42 mg orally 42 liver biopsies 42 prospective observational cohort 42 oral antidiabetes drugs 42 polytherapy 42 dacarbazine 42 cells mcL 42 blind multicentre 42 tipranavir ritonavir 41 aged ≥ 41 pravastatin 41 % CI #.#-#.# [006] 41 anticoagulation therapy 41 hemodialysis patients 41 multicenter clinical 41 relapsed refractory ALL 41 prospective multicentre 41 newer antipsychotic medications 41 randomized trials 41 dose cytarabine 41 benazepril 41 paclitaxel carboplatin 41 doxorubicin cyclophosphamide 41 olmesartan 41 BEACOPP 41 diagnosed glioblastoma 41 Contrave# 41 dacarbazine chemotherapy 41 dose escalation 41 prospective longitudinal 41 multicenter Phase 41 laboratory abnormalities 41 μg doses 41 Edge STudy 41 non myeloablative 41 pharmacologically active isomer 41 #mg BID [002] 41 liver transplant recipients 41 VADT 41 underwent resection 41 non valvular atrial 41 copies ml 41 Endeavor Resolute DES 41 XIENCE V demonstrated 41 p = #.# [002] 41 glimepiride 41 ALA PDT 41 Randomised 41 MetS 41 AGILECT R 41 pegylated liposomal doxorubicin 41 aspartate aminotransferase AST 41 daunorubicin 41 mmol L 41 golimumab CNTO 41 dihydroergotamine DHE 41 Apidra ® 41 budesonide pMDI 41 HCV genotype 41 bortezomib refractory 41 CsA 41 longitudinal study 41 mg m 41 Subjects 41 nalbuphine 41 mild gestational diabetes 41 telaprevir dosing 41 sirolimus eluting 41 nonresponders 41 Health Initiative Observational 41 posttreatment 41 NATRECOR R 41 milrinone 41 CARDIA study 41 letrozole 41 timepoint 41 fluoxetine 41 mCi m 2 41 achieved statistical significance 41 nucleoside naive 41 chemoradiation 41 ACTEMRA TM 41 confidence interval #.#-#.# 41 lanthanum carbonate 41 MIRAPEX 41 diastolic BP 41 seronegative 41 Phase III randomized controlled 41 Atherosclerosis MESA 41 DMARD 41 urate lowering therapy 41 biochemical relapse 41 Gy 41 RCTs 41 neoadjuvant chemotherapy 41 relapsed myeloma 41 glulisine 41 interpersonal psychotherapy 41 tenofovir Viread 41 PegIntron 41 low dose cytarabine 41 LNG IUS 41 HYVET 41 rFSH 41 observational cohort study 41 ACE inhibitor 41 41 unresectable stage 41 stable angina 41 sirolimus eluting stents 41 fibrinolytic therapy 41 bezafibrate 41 immunosuppressive regimen 41 Pegasys ® 41 HAART regimen 41 ABVD 41 pyridostigmine 41 REBETOL 41 factorial 41 nelfinavir 41 mg eq 41 bronchial thermoplasty 41 low dose Iluvien 41 external beam radiotherapy 41 dexamethasone 41 enoxaparin 41 baseline A1C 41 posttest 41 ± SD 41 metastatic renal cell carcinoma 41 μg kg 41 subcutaneously administered 41 irinotecan cisplatin 41 multicenter Phase III 41 3mg/kg 41 MMSE scores 41 QTcF 41 KRAS mutations occur 41 HCV infected 41 diagnosed multiple myeloma 41 opioid naive 41 Multi Ethnic Study 41 FOLPI 41 undetectable HBV DNA 41 FFNS 41 idarubicin 41 mm Hg diastolic 41 fluticasone propionate 41 coronary revascularization 41 seroconverted 41 esomeprazole 41 mm Hg 41 beclomethasone 41 placebo controlled studies 41 mg dL 41 mg q#h 41 tertiles 41 noninferior 41 nonmetastatic prostate cancer 41 plus gemcitabine 41 chlorthalidone 41 #Gy 41 vinorelbine 41 CML CP 41 telaprevir dosed 41 observer blinded randomized 41 metformin monotherapy 41 metastatic CRPC 41 1mg 41 chemotherapy docetaxel 41 squamous histology 41 placebo controlled multicenter 41 GG genotype 41 clomipramine 41 Thrombolysis 41 Secondary endpoints include 41 postmenopausal 41 tenofovir FTC 41 FOLFOX4 41 peginterferon alpha 2a 41 treated nonoperatively 41 comparator PI 40 pegylated interferon alpha 40 median CD4 40 Framingham Offspring Study 40 receiving VICTRELIS 40 depressive symptoms 40 randomly sampled 40 Young Adults CARDIA 40 LAB GHRH 40 Viread Emtriva Sustiva 40 tumor histology 40 statistically significant improvement 40 creatinine clearance 40 tamsulosin 40 EINSTEIN DVT 40 RSD# oral 40 vitamin D3 supplements 40 subanalysis 40 eosinophilic asthma 40 vaginal progesterone gel 40 genotype 1b 40 colorectal adenoma 40 PON1 activity 40 multicenter placebo controlled 40 Secondary endpoints 40 atazanavir 40 lipid lowering therapy 40 Study ADX# 40 pooled comparator 40 GH deficient 40 corrected QT interval 40 Patients 40 thiazide diuretics 40 de novo AML 40 endoscopic remission 40 methotrexate 40 progressive PsA 40 fasting insulin 40 paricalcitol 40 randomizing 40 pharmacokinetics PK 40 IV bolus 40 mmHg 40 cholinesterase inhibitor 40 Intervention Effectiveness 40 estramustine 40 unfractionated heparin UFH 40 randomise 40 null responder HCV 40 haloperidol 40 IMPACT DCM trial 40 plasma folate 40 underwent bariatric surgery 40 euglycemic clamp 40 5mg/kg 40 NSABP B 40 oral antidiabetic medication 40 HOPE TOO 40 moderate hepatic impairment 40 atorvastatin #mg 40 IIIa inhibitors 40 severe exacerbations 40 VIRAMUNE XR 40 pharmacokinetic parameters 40 PEG Intron 40 papillary renal cell carcinoma 40 hip BMD 40 dyads 40 pg mL 40 events TEAEs 40 hypogonadal 40 asymptomatic metastatic 40 μg dose 40 diagnosed glioblastoma multiforme 40 postop 40 intramuscular IM 40 cognitive behavioral therapy 40 HCV genotype 1 40 MADIT II 40 corticosteroid dose 40 multivariate analyzes 40 mg/m2/day 40 multiple ascending dose 40 treated nonsurgically 40 refractory NSCLC 40 systemic corticosteroid 40 placebo controlled trials 40 alfa 2a 40 antithymocyte globulin 40 Index CDAI 40 factorial design 40 comorbid ADHD 40 tDCS 40 mL/min/#.# m 2 40 abnormal Pap test 40 plasma glucose 40 ELBW infants 40 patients evaluable 40 abacavir Ziagen 40 mcg dose 40 nicardipine 40 posttransplant 40 Placebo controlled 40 inhalations twice 40 lipid lowering agents 40 electroencephalograms EEG 40 CIMZIA TM certolizumab pegol 40 antidepressant therapy 40 amisulpride 40 olanzapine 40 PREZISTA r arm 40 REYATAZ ritonavir 40 methotrexate MTX 40 dose escalation trial 40 viral kinetic 40 meta regression 40 psychoeducation 40 bupropion XL 40 hepatitis C genotype 40 metreleptin 40 infliximab 40 receiving CIMZIA #mg 40 enalapril 40 bendamustine 40 RG# ITMN 40 pharmacodynamics 40 stellate ganglion block 40 achieved sustained virological 40 endometrial thickness 40 Viread Emtriva 40 glycoprotein IIb IIIa inhibitor 40 HER2 positive metastatic breast 40 intratympanic 40 g dL 40 exemestane 40 Stage IIIb 40 pre menopausal 40 ejection fractions 40 prospectively 40 Fasting plasma glucose 40 salmeterol fluticasone 40 adriamycin 40 concurrent chemoradiation 40 chemotherapy regimen 40 cirrhotic 40 splenectomized 40 NPH insulin 40 mCi kg 40 AVOREN 40 SHBG levels 40 oxycodone IR 40 Proellex TM 40 tolterodine 40 #mg dosing group 40 antiretroviral regimen 40 carboplatin paclitaxel 40 lenalidomide dexamethasone 40 β blockers 40 MBq 40 #mmHg [001] 40 severe neutropenia 40 BENICAR HCT 40 8mg 40 quetiapine risperidone 40 intravenous cyclophosphamide 40 plasma selenium 40 ER CHOP 40 mg m² 40 placebo p = 40 CANCIDAS 40 serum lipid levels 40 TAXUS ARRIVE 40 dosed 40 dose regimen 40 ongoing Phase 1b 40 tertile 40 androgen suppression 40 plus glycoprotein IIb 40 rt PA 40 serodiscordant couples 40 irregular menses 40 adenoma recurrence 40 heFH 40 glipizide 40 operable breast cancer 40 chemoradiotherapy 40 multicenter phase 40 insulin lispro 40 randomized controlled clinical trials 40 intravenous picoplatin 40 IELT 40 nonsignificant 40 relapsing remitting MS RRMS 40 ATACAND 40 paroxysmal AF 40 overt nephropathy 40 #mg [003] 40 randomly assigns 40 unsupplemented 40 psychoeducational 40 docetaxel chemotherapy 40 antihypertensive drugs 40 beta blocker therapy 39 mg tid 39 2mg 39 APTIVUS ritonavir 39 pioglitazone 39 events SAEs 39 retinal vein occlusion induced 39 AVODART 39 prescribed statins 39 fallopian tube cancers 39 subcutaneous enoxaparin 39 NMES 39 THIS STUDY 39 diagnosed Ph + 39 CLARITY study 39 ALT flares 39 RE LY ® 39 GH deficiency 39 FOSRENOL ® 39 asthma exacerbation 39 prehypertensive 39 MMSE score 39 FOLFOX6 chemotherapy regimen 39 attain statistical significance 39 affective psychosis 39 Phase 1b clinical 39 evaluated 39 rosuvastatin #mg 39 prepubertal 39 CLARITY TIMI 39 olanzapine LAI 39 MGd 39 recurrent acute pancreatitis 39 tapentadol ER 39 sorafenib Nexavar ® 39 TOHP 39 neoadjuvant treatment 39 Rating Scale MADRS 39 heavily pretreated patients 39 valsartan 39 observational studies 39 androgen deprivation 39 nonautistic 39 mg doses 39 imipramine 39 nifedipine 39 lipid lowering drugs 39 opioid dependent 39 NMIBC 39 antiandrogen 39 number NCT# ClinicalTrials.gov 39 biphasic insulin aspart 39 cisplatin vinorelbine 39 angiotensin converting enzyme inhibitor 39 transaminase elevations 39 AIR CF3 39 fluorouracil 39 Helicobacter pylori eradication 39 habitual snoring 39 multinational multicenter randomized 39 axillary node dissection 39 metformin IR 39 salmeterol fluticasone propionate 39 idraparinux 39 deferoxamine 39 ARB telmisartan 39 tiotropium 39 urate lowering 39 FOLFIRI 39 glargine 39 MVax R 39 caspofungin 39 interferon ribavirin 39 NSTEMI 39 intraperitoneal 39 Median survival 39 resectable 39 CAMMS# 39 metastatic RCC 39 oral hypoglycemic 39 Multicenter Randomized Double 39 NICE SUGAR 39 risperidone 39 CAVEATS

Back to home page